PortalPublikationenSystemic sclerosis-associated interstitial lung disease in t...

Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region

Standard

Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. / Lescoat, Alain; Huscher, Dörte; Schoof, Nils; Airò, Paolo; de Vries-Bouwstra, Jeska; Riemekasten, Gabriela; Hachulla, Eric; Doria, Andrea; Rosato, Edoardo; Hunzelmann, Nicolas; Montecucco, Carlomaurizio; Gabrielli, Armando; Hoffmann-Vold, Anna-Maria; Distler, Oliver; Ben Shimol, Jennifer; Cutolo, Maurizio; Allanore, Yannick; EUSTAR Collaborators.

in: RHEUMATOLOGY, Jahrgang 62, Nr. 6, 01.06.2023, S. 2178-2188.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lescoat, A, Huscher, D, Schoof, N, Airò, P, de Vries-Bouwstra, J, Riemekasten, G, Hachulla, E, Doria, A, Rosato, E, Hunzelmann, N, Montecucco, C, Gabrielli, A, Hoffmann-Vold, A-M, Distler, O, Ben Shimol, J, Cutolo, M, Allanore, Y & EUSTAR Collaborators 2023, 'Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region', RHEUMATOLOGY, Jg. 62, Nr. 6, S. 2178-2188. https://doi.org/10.1093/rheumatology/keac576

APA

Lescoat, A., Huscher, D., Schoof, N., Airò, P., de Vries-Bouwstra, J., Riemekasten, G., Hachulla, E., Doria, A., Rosato, E., Hunzelmann, N., Montecucco, C., Gabrielli, A., Hoffmann-Vold, A-M., Distler, O., Ben Shimol, J., Cutolo, M., Allanore, Y., & EUSTAR Collaborators (2023). Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. RHEUMATOLOGY, 62(6), 2178-2188. https://doi.org/10.1093/rheumatology/keac576

Vancouver

Lescoat A, Huscher D, Schoof N, Airò P, de Vries-Bouwstra J, Riemekasten G et al. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. RHEUMATOLOGY. 2023 Jun 1;62(6):2178-2188. https://doi.org/10.1093/rheumatology/keac576

Bibtex

@article{1bebefa79bab4ef1b36e6fe13619655c,
title = "Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region",
abstract = "OBJECTIVES: The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) vary between geographical regions worldwide. The objectives of this study were to explore the differences in terms of prevalence, phenotype, treatment and prognosis in patients with SSc-ILD from predetermined geographical regions in the EUSTAR database.MATERIAL AND METHODS: Patients were clustered into seven geographical regions. Clinical characteristics and survival of patients with SSc-ILD were compared among these pre-determined regions.RESULTS: For baseline analyses, 9260 SSc patients were included, with 6732 for survival analyses. The prevalence of SSc-ILD in the overall population was 50.2%, ranging from 44.0% in 'Western Europe and Nordic countries' to 67.5% in 'Eastern European, Russia and Baltic countries'. In all regions, anti-topoisomerase antibodies were associated with SSc-ILD. Management also significantly differed; mycophenolate mofetil was prescribed at baseline in 31.6% of patients with SSc-ILD in 'America (North and South)' and 31.7% in 'Middle East' but only 4.3% in 'Asia and Oceania' (P <0.0001). Patients from 'America (North and South)' and 'Middle East' had the highest survival rate at the end of follow-up (85.8% and 85.2%, respectively).CONCLUSIONS: Our study highlights key differences among regions in terms of clinical presentation and prognosis of SSc-ILD. This work also demonstrates that the management of SSc-ILD is highly variable among the different regions considered, suggesting that efforts are still needed for the standardization of medical practice in the treatment of this disease.",
author = "Alain Lescoat and D{\"o}rte Huscher and Nils Schoof and Paolo Air{\`o} and {de Vries-Bouwstra}, Jeska and Gabriela Riemekasten and Eric Hachulla and Andrea Doria and Edoardo Rosato and Nicolas Hunzelmann and Carlomaurizio Montecucco and Armando Gabrielli and Anna-Maria Hoffmann-Vold and Oliver Distler and {Ben Shimol}, Jennifer and Maurizio Cutolo and Yannick Allanore and {EUSTAR Collaborators} and Ina K{\"o}tter",
note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
year = "2023",
month = jun,
day = "1",
doi = "10.1093/rheumatology/keac576",
language = "English",
volume = "62",
pages = "2178--2188",
journal = "RHEUMATOLOGY",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region

AU - Lescoat, Alain

AU - Huscher, Dörte

AU - Schoof, Nils

AU - Airò, Paolo

AU - de Vries-Bouwstra, Jeska

AU - Riemekasten, Gabriela

AU - Hachulla, Eric

AU - Doria, Andrea

AU - Rosato, Edoardo

AU - Hunzelmann, Nicolas

AU - Montecucco, Carlomaurizio

AU - Gabrielli, Armando

AU - Hoffmann-Vold, Anna-Maria

AU - Distler, Oliver

AU - Ben Shimol, Jennifer

AU - Cutolo, Maurizio

AU - Allanore, Yannick

AU - EUSTAR Collaborators

AU - Kötter, Ina

N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

PY - 2023/6/1

Y1 - 2023/6/1

N2 - OBJECTIVES: The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) vary between geographical regions worldwide. The objectives of this study were to explore the differences in terms of prevalence, phenotype, treatment and prognosis in patients with SSc-ILD from predetermined geographical regions in the EUSTAR database.MATERIAL AND METHODS: Patients were clustered into seven geographical regions. Clinical characteristics and survival of patients with SSc-ILD were compared among these pre-determined regions.RESULTS: For baseline analyses, 9260 SSc patients were included, with 6732 for survival analyses. The prevalence of SSc-ILD in the overall population was 50.2%, ranging from 44.0% in 'Western Europe and Nordic countries' to 67.5% in 'Eastern European, Russia and Baltic countries'. In all regions, anti-topoisomerase antibodies were associated with SSc-ILD. Management also significantly differed; mycophenolate mofetil was prescribed at baseline in 31.6% of patients with SSc-ILD in 'America (North and South)' and 31.7% in 'Middle East' but only 4.3% in 'Asia and Oceania' (P <0.0001). Patients from 'America (North and South)' and 'Middle East' had the highest survival rate at the end of follow-up (85.8% and 85.2%, respectively).CONCLUSIONS: Our study highlights key differences among regions in terms of clinical presentation and prognosis of SSc-ILD. This work also demonstrates that the management of SSc-ILD is highly variable among the different regions considered, suggesting that efforts are still needed for the standardization of medical practice in the treatment of this disease.

AB - OBJECTIVES: The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) vary between geographical regions worldwide. The objectives of this study were to explore the differences in terms of prevalence, phenotype, treatment and prognosis in patients with SSc-ILD from predetermined geographical regions in the EUSTAR database.MATERIAL AND METHODS: Patients were clustered into seven geographical regions. Clinical characteristics and survival of patients with SSc-ILD were compared among these pre-determined regions.RESULTS: For baseline analyses, 9260 SSc patients were included, with 6732 for survival analyses. The prevalence of SSc-ILD in the overall population was 50.2%, ranging from 44.0% in 'Western Europe and Nordic countries' to 67.5% in 'Eastern European, Russia and Baltic countries'. In all regions, anti-topoisomerase antibodies were associated with SSc-ILD. Management also significantly differed; mycophenolate mofetil was prescribed at baseline in 31.6% of patients with SSc-ILD in 'America (North and South)' and 31.7% in 'Middle East' but only 4.3% in 'Asia and Oceania' (P <0.0001). Patients from 'America (North and South)' and 'Middle East' had the highest survival rate at the end of follow-up (85.8% and 85.2%, respectively).CONCLUSIONS: Our study highlights key differences among regions in terms of clinical presentation and prognosis of SSc-ILD. This work also demonstrates that the management of SSc-ILD is highly variable among the different regions considered, suggesting that efforts are still needed for the standardization of medical practice in the treatment of this disease.

U2 - 10.1093/rheumatology/keac576

DO - 10.1093/rheumatology/keac576

M3 - SCORING: Journal article

C2 - 36222557

VL - 62

SP - 2178

EP - 2188

JO - RHEUMATOLOGY

JF - RHEUMATOLOGY

SN - 1462-0324

IS - 6

ER -